We demonstrated that HIF-2α inhibition in conjunction with conventional chemotherapy agents, cisplatin and doxorubicin, effectively alleviates chondrosarcoma malignancy through their synergistic effects on augmenting chondrosarcoma cell death. This evidence concerns the gene EPAS1 and chondrosarcoma.